Drug manufacturer Shire has released the results of a study aimed at tracking the effectiveness of its drug Vyvanse on adolescents diagnosed with ADHD. Currently, the drug is only approved for treatment of children and adults.

"In this study, Vyvanse improved ADHD symptoms of inattention, hyperactivity and impulsivity in adolescents compared to a placebo," said Ann C. Childress, MD, president of the Center for Psychiatry and Behavioral Medicine, Inc. in Las Vega, Nevada and lead investigator for this study. "These results are important as we look for additional ways to effectively manage ADHD symptoms in adolescent patients." [Source: Shire press release]

As a result of the study, Shire plc has submitted a supplemental New Drug Application (sNDA) to the FDA, requesting that Vyvanse be approved for treatment of ADHD in teenagers. There’s no indication as to when, or if, the application will be approved.

Labels: medications, vyvanse, drugs

Posted By: Stefanie Hamilton